


CURRICULUM VITAE



Name: **Raymond David Snyder AM, MB BS, MMed, FRACP, GAICD**

Date of birth: 15 July 1946

Place of birth: Melbourne, Australia

Nationality: Australian

Marital status: Married (with two adult children)

Address: Home 37 Mary Street, St Kilda West 3182, VIC Australia (preferred address)
Office St. Vincent's Hospital, 41 Victoria Pd., Fitzroy 3065, VIC Australia

Telephone office: (03) 9231 3155
home: (03) 9534 1056
mobile: +61 407 319 501 (preferred contact)

E-mail rsnyder@bigpond.net.au

Education: 1952-63 Mount Scopus College, Burwood, Australia
1964-69 University of Melbourne, M.B., B.S.

Degrees: 1969 M.B., B.S. (U. of Melbourne)
1985 M. Med. (U. of Melbourne)

Registration: Med Board Australia # 1666957653
Provider no.: 421 261X

Accreditation: 2018 Good Clinical Practice (GCP) training (June 2018)
2019 Graduate Australian Institute Company Directors

Positions 1970-71 Resident Medical Officer Royal Melbourne Hospital
1972 Medical Registrar Royal Melbourne Hospital
1973-5 Haematology Registrar Royal Melbourne Hospital
1975-76 Fellow, Dept. Developmental Therapeutics M.D. Anderson Hosp. & Tumor Institute, Houston, TX USA.
1976-77 Faculty Associate M.D. Anderson Hosp.
1977-79 Acting oncologist, assistant outpatient physician St. Vincent's Hospital, Fitzroy

CV RD Snyder

	1979-85	Assistant oncologist Assistant to paed haem/oncol clinic	St. Vincent's Hosp. Queen Victoria Med Centre
	1979-93	Consultant	Anti-Cancer Council of Victoria
	1986-14	Oncologist	St. Vincent's Hospital
	1986-2012	Consultant medical officer - oncologist	Goulburn Valley Base Hospital
	2002-	Principal fellow (Associate Professor) Dep Medicine,	St Vincent's Hospital (Melb)
	2004-7	Co-Director of Ca. Services,	St Vincent's Hospital (Melb)
	2007-14	Director of Cancer Services,	St Vincent's Hospital (Melb)
	2007-14	Director of Oncology,	St Vincent's Hospital (Melb)
	20014-	Honorary Oncologist	St Vincent's Hospital (Melb)
	2019	Accredited Medical Panels	Dep Justice and Community Safety
Teaching positions:	1971	Tutor in physiology	Ormond College
	1978-97	Associate, Dep Medicine	(St. Vincent's Hosp.) U. Melbourne
	1998-02	Senior fellow, Dep Medicine	(St. Vincent's Hosp.) U. Melbourne
Postgraduate Diplomas:	1973	Member	Royal Australasian Coll. Physicians
	1977-	Fellow	Royal Australasian Coll. Physicians
	2019-	Graduate	Australian Institute Company Directors
Learned societies:		Medical Oncology Group of Australia	
Learned societies:		Clinical Oncological Society of Australia	
Learned societies:		American Society Clinical Oncology Int Assoc Study Lung Cancer	
Current committees:		Member and Hon Treasurer, Comm. of Management, Eastern Pall Care Member, Standing Research Sub-Committee, CCV	
Important past posts:		Chairman, Medical Oncology Group of Australia (1990-5, 1996-8) Chairman, SAC Medical Oncology, RACP Chairman, Senior Medical Staff Association, St Vincent's Hosp Chairman, Board ANZ Breast Cancer Trials Group (1995-2005) Chairman, Vic Cooperative Oncology Group (2002-5) Member, Ministerial Taskforce for Cancer (Victoria) (2003-7) Chairman, Comm. of Management, Eastern Pall Care (2008-10) Member, Management Committee, Biogrid Member, Board Victorian Breast Cancer Research Consortium Member Reference Group, Victorian Cancer Agency (2017- 8)	
Awards	2014	ANZ BCTG Gold Medal	
	2017	Member (AM) in General Division of the Order of Australia	

CV RD Snyder

Publications:

Snyder RD, Mavligit GM, Valdivieso M, Gutterman JU & Burke JS. Histiocytic lymphoma in the brain as the only manifestation of relapse following remission maintenance with B.C.G. immunotherapy. *Cancer* 39, 1997-2000, 1977.

Hortobagyi GN, Gutterman JU, Snyder RD, Richman SP, Hersh EM. Pseudomonas vaccine: a phase I evaluation for cancer research. *Cancer Immunol Immunotherap* 4, 201-7, 1978.

Snyder RD, Mavligit GM, Valdivieso M. Adenocarcinoma of unknown primary site: a clinicopathological study. *Med Ped Oncol* 6,289-94, 1979.

Snyder RD, Hortobagyi GN, Bodey GP, Gutterman JU, Hersh EM. Combination therapy for advanced malignant melanoma with BCNU, pseudomonas vaccine and heparin. *J Surg Oncol* 16, 87-92, 1981.

Snyder RD and Burns WI. The cost of clinical trials in cancer. *Aust Health Rev* 5, 2, 27-8, 1982.

Hillcoat BL, Levi J, Snyder RD. Preparation and administration of antineoplastic agents (risks and recommendations). *Med J Aust* 1, 424-8, 1983.

Snyder RD. Alternative cancer treatments: understanding their attraction. *Patient management* 67-73, Aug 1983.

Snyder RD, Bishop J, Brodie G, et al. Phase I study of epirubicin given on a weekly schedule. *Cancer Treat Rep* 71, 273-276, 1987.

Coates A, GebSKI V, Bishop JF, Jeal JN, Woods RL, Snyder R, Tattersall MHN, Byrne M, Harvey V, Gill G, Simpson J, Drummond R, Browne J, van Cooten R, and Forbes JF, for the A-NZ Breast Cancer Trials Group, COSA. Improving the quality of life during chemotherapy for advanced breast cancer. *N Engl J Med* 317, 1490-5, 1987

Levi JA, Thomson D, Sandeman T, Tattersall M, Raghavan D, Byrne M, Gill G, Harvey H, Burns I and Snyder R. A prospective study of cisplatin-based combination chemotherapy in advanced germ cell malignancy: role of maintenance and long-term follow-up. *J Clin Oncol* 6, 1154-1160, 1988

Levi JA, Thomson D, Bishop J, Raghavan D, Tattersall M, Byrne M, Gill G, Harvey V, Snyder R, Dalley D and Sandeman T for the Australasian Germ Cell Trial Group. Dose intensity and outcome with combination chemotherapy for germ cell carcinoma. *Eur J Cancer Clin Oncol* 25, 1073-77, 1989

Hurley SF, Huggins RM, Snyder RD and Bishop JF. The cost of breast cancer recurrences. *Br J Cancer* 65, 449-455, 1992

Gill PC, GebSKI V, Snyder R, et al: Randomised comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival in patients with metastatic breast cancer. *Ann Oncol* 4, 741-744, 1993

Levi JA, Raghavan D, Harvey V et al: The importance of bleomycin in combination chemotherapy for good prognosis germ cell carcinoma. *J Clin Oncol* 11:1300-1305, 1993

Levi JA, Beith JM, Snyder RD, et al: Phase II study of high dose epirubicin in combination with cyclophosphamide in patients with advanced breast cancer. *Aust NZ J Med* 25:474-478, 1995

Kissane DW, Bloch S, Dowe DL, Snyder RD, Onghena P, McKenzie DP, Wallace CS: The Melbourne Family Grief Study, I: Perceptions of family functioning in bereavement. *Am J Psych* 153(5):650-8, 1996

Kissane DW, Bloch S, Onghena P, McKenzie DP, Snyder RD, Dowe DL: The Melbourne Family Grief Study, II: Psychosocial morbidity and grief in bereaved families. *Am J Psych* 153(5):659-66, 1996

CV RD Snyder

Tebbutt NC, Snyder RD and Burns WI: An analysis of the outcomes of treatment of small cell lung cancer in the elderly. *Aust NZ J Med* 27:160-4, 1997

Bishop J, GebSKI V, Simes J, Dewar J, Snyder R, Byrne M, Forbes J. Sequential randomized studies in metastatic breast cancer: CMFP vs doxorubicin/cyclophosphamide, mitoxantrone, or paclitaxel. *Oncology* 13(12) supp 7, 1-6, 1999

Lethborg CE, Kissane D, Burns WI, Snyder R. "Cast Adrift": The experience of completing treatment among women with early stage breast cancer. *J Psychosocial Oncology* 18(4) 72-90, 2000

Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Janicke F, Pluzanska A, Dank M, Becquart D, Bapsy PB Salminen E, Snyder R, Lassus M, Verbeek JA, Staffler B, Chaudri-Ross HA, Dugan M. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. *J Clin Oncol.* 19:2596-606, 2001

Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleebom HP, Jaenicke F, Pluzanka A, Dank M, Becquart D, Bapsy PB, Salminen E, Snyder R, Chaudri-Ross H, Lang R, Wyld P and Bhatnagar A. phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in post-menopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. *J Clin Oncol* 21:2101-2109, 2003

Hill PA, Goodman DG and Snyder RD. Nephrotic syndrome associated with carcinoma of the breast. *Clin Nephrol* 60:437-8, 2003

Berclaz G, Li S, Price KN, Coates AS, Castiglione-Gertsch M, Rudenstam C-M, Holmberg SB, Lindtner J, Erzen D, Collins J, Snyder R, Thurlimann B, Fey MF, Mendiola C, Werner Dudley I, Simoncini E, Crivellari D, Gelber RD and Goldhirsch A. Body mass index as a prognostic factor in operable breast cancer: the International Breast Cancer Study Group experience. *Ann Oncol* 15:875-884, 2004

Kissane DW, Love A, Hatton H, Bloch S, Smith G, Clarke DM, Miach P, Ikin J, Ranieri N, and Snyder RD. Effect of cognitive-existential group therapy on survival in early-stage breast cancer. *J Clin Oncol* 12: 4255-4260, 2004

Bernhard J, Zahrieh D, Coates AS, Gelber RD, Castiglione-Gertsch M, Murray E, Forbes JF, Pery L, Collins J, Snyder R, Rudenstam C-M, Crivellari D, Veronisi A, Thurlimann B, Fey MF, Price KN, Goldhirsch A and Hurney C for IBCSG. Quantifying trade-offs: quality of life and quality-adjusted survival in a randomized trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer. *Br J Cancer* 91, 1893-1901, 2004

Colleoni M, Zahrieh D, Gelber RD, Holmberg SB, Mattsson JE, Rudenstam C-M, Lindtner J, Erzen D, Snyder R, Collins J, Fey MF, Thurlimann B, Crivellari D, Murray E, Mendiola C, Pagani O, Castiglione-Gertsch M, Coates AS, Price K, and Goldhirsch A. Site of primary tumor has a prognostic role in operable breast cancer: The International Breast Cancer Study Group Experience. *J Clin Oncol* 23:1390-1400, 2005

Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Anton A, Lluch A, Kennedy J, O'Byrne K, Conte P, Green M, Ward C, Mayne K, and Extra J-M. Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Administered as First-Line Treatment: Results of a Randomized Phase II Trial by the M77001 Study Group. *J Clin Oncol*, 23: 4265-4274, 2005

Newnham GM, Burns WI, Snyder RD, Dowling AJ, Ranieri NF, Gray EL, and McLachlan S-A. Attitudes of oncology health professionals to information from the Internet and other media. *MJA*, 183: 197-200, 2005

CV RD Snyder

Albain KS, de la Garza Salazar J, Pienkowski T, Aapro M, Bergh J, Caleffi M, Coleman R, Eiermann W, Icli F, Pegram M, Piccart M, Snyder R, Toi M, Hortobagyi GN. Reducing the global breast cancer burden: the importance of patterns of care research. *Clin Breast Cancer*. 6(5):412-20, 2005

Dawson S-J, Ranieri NF, Snyder RD, McLachlan SA, Burns WI, Newnham GM, Francis PA and Dowling AJ. Central nervous system metastases in women with HER-2 positive metastatic breast cancer after treatment with trastuzumab. *Asia-Pac J Clin Oncol* 2: 50-56, 2006

Newnham G M, Burns WI, Snyder RD, Dowling AJ, Ranieri NF, Gray EL, and McLachlan S-A. Information from the Internet: attitudes of Australian oncology patients. *Intern Med J* 36:718-723, 2006

Kissane DW, Grabsch B, Clarke DM, Smith GC, Love AW, Bloch S, Snyder RD, Li Y. Supportive-expressive group therapy for women with metastatic breast cancer: survival and psychosocial outcome from a randomized controlled trial. *Psycho-Oncology* 16: 277-286, 2007

Gianni L, Cole BF, Panzini I, Snyder R, Holmberg SB, Byrne M, Crivellari D, Colleoni M, Aebi S, Simoncini E, Pagani O, Castiglione-Gertsch M, Price KN, Goldhirsch A, Coates AS, Ravaoli A. Anemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study Group. *Support Care Cancer*. 16(1):67-74, 2008

Pestalozzi BC, Zahrieh D, Mallon E, Gusterson BA, Price KN, Gelber RD, Holmberg SB, Lindtner J, Snyder R, Thurlimann B, Murray E, Viale G, Castiglione-Gertsch M, Coates AS, and Goldhirsch A. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: Combined results of 15 International Breast Cancer Study Group Clinical Trials. *J Clin Oncol* 26:3006-3014, 2008

Green MD, Francis PA, GebSKI V, Harvey V, Karapetis C, Chan A, Snyder R, Fong A, Basser R & Forbes JF, on behalf of the Australian New Zealand Breast Cancer Trials Group. Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer. *Ann Oncol* 11:1813-7, 2009

Snyder RD, Boyle FM, Chan A, Craft PS, De Boer R, Mainwaring PN, Mccarthy NJ and Wilcken NR. Clinical recommendations for the use of lapatinib ditosylate plus capecitabine for patients with advanced or metastatic HER2-positive breast cancer. *Asia-Pac J Clin Oncol* 5: 4-16, 2009.

Goel S, Chirgwin J, Francis P, Stuart-Harris R, Dewar J, Mileskin L, Snyder R, Michael M, Koczwara B. Rational use of trastuzumab in metastatic and locally advanced breast cancer: implications of recent research. *Breast*. Apr;20(2):101-10, 2011.

Aebil S, Sun Z, Braun D, Price KN, Castiglione-Gertsch M, Rabaglio M, Gelber RD, Crivellari D, Lindtner J, Snyder R, Karlsson P, Simoncini E, Gusterson BA, Viale G, Regan MM, Coates AS, & Goldhirsch A. Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: Long-term follow up on IBCSG Trial IX. *Ann Oncol* 22: 1981-1987, 2011

Martin M, Roche H, Pinter T, Crown T, Kennedy MJ, Provencher L, Priou F, Eiermann W, Adrover E, Lang I, Ramos M, Latreille J, Jagiełło-Gruszfeld A, Pienkowski T, Alba E, Snyder R, Almel S, Rolski J, Munoz M, Moroosse R, Hurvitz S, Banos A, Adewoye H, Hei Y-J, Lindsay M-A, Rupin M, Cabaribere D, Lemmerick Y, Mackey JR, on behalf of the TRIO 010 investigators. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. *Lancet Oncology* 22 Mar 2011

Say LN, Burns WI, Snyder RD, Newnham GM, McLachlan S-A, Liew D and Dowling AJ. A retrospective cohort study of metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy, with an exploratory analysis of changing serum carcinoembryonic antigen level. *Asia-Pac J Clin Oncol* 8: 172-179 2012

CV RD Snyder

Hyams DM, Chan A, de Oliveira C, Snyder R, Vinholes J, Audeh MW, Alencar VM, Lombard J, Mookerjee B, Xu J, Brown K, and Klein P. Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study. *Invest New Drugs*. June 26, 2013 (epub)

Metzger-Filho O, Sun Z, Viale G, Price KN, Crivellari D, Snyder RD, Gelber RD, Castiglione-Gertsch M, Coates AS, Goldhirsch A, and Cardoso F. Patterns of recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: Results from International Breast Cancer Study Group Trials VIII and IX. *JCO*. 31. 3083-3090, 2013

Wilcken N, Zdenkowski N, White M, Snyder R, Pittman K, Mainwaring P, Green M, Francis P, De Boer R, Colosimo M, Chua S, Chirgwin J, Beith J and Bell R. Systemic treatment of HER2-positive metastatic breast cancer: a systemic review. *Asia-Pac J Clin Oncol* 10 (Suppl. 4) 1-14, 2014

Parker C, Snyder R, Jefford M, Dilts D, Wolfe R, and Millar J. A randomized controlled trial of an additional funding intervention to improve clinical trial enrollment. *J Natl Compr Canc Netw*, 1104-1110, 2017

Lee, B, Tran, B, Hsu, AL, Taylor, GR, Fox, SB, Fellowes, A, Marquis, R, Mooi, J, Desai, J, Doig, K, Ekert, P, Gaff, C, Herath, D, Hamilton, A, James, P, Roberts, A, Snyder, R, Waring, P and McArthur, G. (2018), Exploring the feasibility and utility of exome scale tumour sequencing in a clinical setting. *Intern Med J*, 48: 786-794, 2018

Abstracts:

Snyder RD, Mavligit GM, Valdivieso M, Haynie TP. Natural history study of adenocarcinoma unknown primary site as a definitive diagnosis. *Proc Am Soc Clin Oncol* 18, 346, C-318, 1977

Snyder RD, Benjamin RS, Rodriguez V, Bodey GP. Phase I/II study of high dose Baker's antifol with citravorum factor rescue. *Proc Clin Oncol Soc Aus* 1977

Snyder RD, Buckley J, Mavligit G. Important prognostic factors in the survival of patients with pancreatic cancer. *Proc Clin Oncol Soc Aus* 1979

Basser R, O'Neill A, Martinelli G, Nasi ML, Peccatori F, Cinieri S, Snyder R, Yeo W, Aebi S, Green M. Randomized trial comparing up-front, multi-cycle dose-intensive chemotherapy (CT) versus standard dose CT in women with high-risk stage 2 or 3 breast cancer (BC): First results from IBCSG Trial 15-95. *Proc Am Soc Clin Oncol* 22: page 6, 2003 (abstr 20)

Extra J-M, Cognetti F, Chan S, Maraninchi D, Snyder R, Lluch A, Tubiana-Hulin M, Grimes D, Mayne K, Marty M. Randomised phase II trial (M77001) of trastuzumab (Herceptin®) plus docetaxel versus docetaxel alone, as first-line therapy in patients with HER2-positive metastatic breast cancer. *European Journal of Cancer Supplements*; Vol. 1, No. 5, September 2003, page S202 (abstr 672)

Colleoni M, Gelber S, Snyder R, Holmberg SB, Fey M, Thurlimann B, Lindtner J, Byrne M, Mendiola C, Coates AS. Randomised comparison of adjuvant tamoxifen versus no hormonal treatment for premenopausal women with node-positive, early stage breast cancer: first results of International Breast Cancer Study Group Trial 13-93. *Proc Am Soc Clin Oncol* 23: page 10, 2004 (abstr 532)

Extra J-M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Anton A, Marty M. Long term survival demonstrated with trastuzumab plus docetaxel: 24 month data from a randomized trial (M77001) in HER-2 positive metastatic breast cancer. *J Clin Oncol* 23:61s, 2005 (suppl, abstr 555)

Hyams DM, de Oliveira C, Snyder R, Klein P, Vinholes J, Audeh MW, Alencar V, Lombard J, Mookerjee B, Xu J, Chan A. Cediranib in Combination with Fulvestrant in Hormone-Sensitive Metastatic Breast Cancer: A Phase II Randomized Study. *Cancer Res* 2009;69 (suppl.) (24): Abstract nr 204

CV RD Snyder

Thesis:

Prognostic factors in pancreatic cancer. (M. Med, U. Melbourne, 1985)

Review articles:

Snyder RD. Some aspects of the development of methotrexate therapy. Clin and Exp Pharmacol & Physiol supp 5, 1-4, 1979

Snyder RD and Schwarz MA. Clinical trials in cancer medicine. Aust Family Phys 9, 23-6, 1980.

Snyder RD. Unproven cancer remedies. Australian Prescriber 10, 16-7, 1987.

Snyder RD. Tumor necrosis factor. Patient Management 13, 1, 71-2, 1989.

Snyder R. The management of ovarian carcinoma. Australian Prescriber 12, 96-7, 1989.

Snyder RD. Clinical perspectives: Revolutionary and evolutionary progress in breast cancer. Aust NZ J Med 27, 523-5, 1997.

Snyder RD. New and old targets for breast cancer treatment. Current Therapeutics 40, 6, 17-21, 1999.

Snyder RD. Clinical perspectives: New Concepts in breast cancer therapy. Intern Med J 34: 266-269, 2004.

Snyder RD. Aromatase inhibitors in the hormonal treatment of breast cancer. Med Today 6, 7:99-100, 2005.

12 Nov 2019